Lung Adenocarcinoma Treatment Market Trends

• Market growth is significantly propelled by the emergence of new and effective treatments, particularly targeted therapies and immunotherapies. According to the National Cancer Institute, the adoption of these therapies has increased by 15% annually over the past five years. These therapies are gaining traction not only for their ability to improve patient outcomes but also for their reduced side effects compared to traditional chemotherapy.
  
• Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs), focus on specific molecules that influence the growth and spread of cancer cells.
  
• For instance, the American Cancer Society reports that these therapies have shown a 25% improvement in survival rates for patients with NSCLC. Their proven efficacy in treating NSCLC has established them as the standard of care for select patients with advanced NSCLC.